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Summary The predictive value of silver stained nucleolar organiser regions (AgNORs) was assessed in 229
patients with transitional cell bladder cancer followed up for over 10 years. The AgNORs were enumerated in
pretreatment biopsy specimens. The AgNORs were related to clinical stage (T)(P = 0.0111), papillarity
(P<0.0001), WHO grade (P<0.0001), DNA ploidy (P = 0.0010) and S-phase fraction (P<0.0001). Tumours
presenting with pelvic lymph node involvement (P= 0.0085) or metastasis (P = 0.0780) at the time of
diagnosis had more AgNORs than tumours confined to the bladder wall. Progression in T-, N- and
M-categories (P = 0.0010-0.0030) was related to AgNORs and consequently they predicted bladder cancer
related survival (P= 0.0005). The diploid tumours could be regrouped according to survival by AgNORs
(P = 0.0001). In papillary tumours AgNORs predicted progression (P = 0.0110) and survival (P = 0.0038). In
Ta-TI tumours AgNORs predicted progression (P= 0.11) and survival (P= 0.0751) and also in T2-T3
tumours AgNORs contributed to survival significantly (P= 0.0039). The AgNORs subdivided WHO grade III
tumours according to their ability to progress during the follow-up time (P = 0.0711). In a multivariate
analysis AgNORs predicted progression independently in Ta-TI category (P= 0.0165).' AgNORs predicted
recurrence free period like SPF (P = 0.0010). In conclusion, AgNORs are inferior to classic prognostic factors
or DNA flow cytometric variables in muscle invasive bladder cancers whereas they have independent
predictive value in superficial cancers.
Subjective grading systems are unable to precisely predict
cancer behaviour (Blomjous et al., 1989; Eskelinen et al.,
1991a; Lipponen & Eskelinen, 1990a). To obtain more accu-
rate pretreatment estimates of survival, quantitative methods
(Blomjous et al., 1989; Eskelinen et al., 1991a; Lipponen &
Eskelinen, 1990a, b, c) have been tested to define new clini-
cally relevant variables in place for subjective grading (Ooms
et al., 1983). Particularly, quantitative variables reflecting
proliferative activity of cancer cells have had the highest
predictive potential (Blomjous et al., 1989; Eskelinen et al.,
1991a; Lipponen & Eskelinen, 1990c; Lipponen et al., 1991b).
Accordingly, S-phase fraction, DNA ploidy (Blomjous et al.,
1989; Lipponen et al., 1991b) and mitotic activity (Lipponen
& Eskelinen, 1990b; Lipponen et al., 1990c) are significant
predictors in transitional cell bladder cancer including similar
prognostic information (Lipponen et al., 1991c). The AgNOR
technique (Smith & Crocker, 1988) permits the estimation of
proliferative activity and clinical behaviour of several malig-
nancies by means of light microscopy (Crocker et al., 1989).
In bladder cancer the results presented until now are contro-
versial in terms of survival and progression (Cairns et al.,
1989; Ooms & Veldhuizen, 1989; Mansour et al., 1990; Lip-
ponen & Eskelinen, 1991a). To establish the predictive value
of AgNORs in bladder cancer a series of 229 patients with a
bladder cancer followed up for over 10 years was analysed
using AgNOR method (Smith & Crocker, 1988). Moreover,
the relationship between DNA index (DI), S-phase fraction
(SPF) and AgNORs was assessed.
Patients and methods
Patients, treatment andfollow-up
The study comprised patients with a newly diagnosed transi-
tional cell bladder cancer at Kuopio University Hospital
in 1965-1989. TIS tumours (UICC, 1978) were not included.
The follow-up analysis was done in January 1990 and
the mean (s.d.) observation time was 10.5 (3.9) years
(Range 4-24). In total there were 229 patients of ages 45-84
years (mean (s.d.), 66.1 (12.6)) the female/male ratio being
46/183. Occasionally patients were excluded from the series
because of insufficient follow-up histories, missing or insuffi-
cient pretreatment biopsy specimens. The treatment and
follow-up investigations were done according to uniform
guidelines (Zingg & Wallace, 1985). Superficial tumours were
treated by transurethral resection and prophylactic intra-
vesical chemotherapy was used in 39 cases. The clinical
staging of tumours was based on results of intravenous
pyelography, transurethral biopsy, cytological examination
and bimanual palpation under anesthesia. In many of muscle
invasive tumours during the latest years a computerised
tomography or ultrasound examination was done. Screening
for metastases included chest radiography, laboratory tests,
abdominal ultrasound, and when appropriate, bone scinti-
graphy and lymphography. TNM classification of tumours
was done according to UICC (UICC, 1978). The follow-up
investigations were done at 3 month intervals during the first
2 years and thereafter at 6 month intervals (Zingg & Wallace,
1985). The recurrence free period (RFP) was defined as the
time from primary treatment to the first observed recurrence
in the bladder. Recurrence rate (RR) was calculated as the
number of recurrences divided by months offollow-up x 100.
The majority of patients who died were autopsied to ascer-
tain the extent and metastasis of tumours.
Histologicalgrading
Pretreatment biposy specimens from the primary tumours
were fixed in buffered formalin (pH = 7.0), embedded in
paraffin, sectioned at 5 gim and stained with hematoxylin and
eosin. The grading was done by a.board certified pathologist
according to WHO (Mostofi, 1973). The growth pattern of
tumours was recorded and the tumours were divided into
papillary or non-papillary nodular types. The distribution of
patients into WHO grade and clinical stage categories is
shown in Table I.
Stainingfor AgNORs
The method described by Smith and Crocker (Smith &
Crocker, 1988) was used. In brief; 5 Im thick sections were
cut from paraffin embedded biopsy specimens, dewaxed in
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Table I The distribution of229 patients into WHO grade and clinical
stage categories
Clinical stage
Histological grade Ta Ti T2 T3 T4 Total
I 3 61 13 4 2 83
II 45 34 16 5 100
III 11 13 12 10 46
Total 3 117 60 32 17 229
xylene (5 min) and rehydrated through ethanols to distilled
deionised water. The AgNOR solution was made by dissolv-
ing gelatine in 1 g dl aqueous formic acid at concentration of
2 g dl. This solution was mixed (1:2) with 50 gdl aqueous
silver nitrate solution which was the final solution used in
staining procedure. A staining time of 38 min was used. The
optimal staining time was tested before the whole series was
stained (Lipponen & Eskelinen, 1991a). For counting the
AgNORs the section were examined under an oil immersion
lens at a magnification of 1000 x. The areas of most atypical
histology were analysed avoiding sample margins and necro-
tic areas. In every section 70 nuclei were examined in the
centres of seven fields, ten neighbouring nuclei in each. The
maximum number of AgNORs visible at the same time
within the nucleus was recorded by focusing the microscope.
AgNORs were identified as recommended by Crocker et al.
(Crocker et al., 1989) by counting all separate silver stained
structures when could be clearly resolved within a cluster as
well as AgNORs lying free within the nucleoplasm. In the
present analysis the mean number of AgNORs/nucleus is
used. The AgNORs in normal perivesical lymph node and in
WHO grade III tumour are shown in Figures la and b. The
AgNORs were counted twice in 15 random samples and the
intraobserver error was <5%.
Flow cytometry
The method and results have been reported previously except
data related to recurrences. The reader is referred to original
text (Lipponen et al., 1991b) for details. Tumours with a
DNA index,< 1.05 were considered diploid.
Statistical methods
SPSS/PC + V3.1 program package were used in a Toshiba
T3200 computer. In survival analysis life-table method was
used with Lee-Desu statistics (Lee & Desu, 1972). In the
first analysis all cases were included whereas the second
analysis included papillary tumours alone. In the third
analysis Ta-Tl and T2-T3 tumours were separately analysed.
In addition, the predictive value of AgNORs was assessed
within WHO grades and within DNA ploidy groups. The
numerical data is expressed as mean( ± s.e.). The specific test
used in comparing the differences are indicated when appro-
priate.
Results
All cases
The number of AgNORs was significantly related to clinical
stage, papillarity, WHO grade, DNA ploidy and S-phase
fraction (Table II). Twenty-six tumours with pelvic lymph
node metastasis at the time of diagnosis had more AgNORs,
3.8 (0.3) than tumours confined to bladder wall (n = 203), 3.0
(0.9), (P = 0.0085). Seven tumours with distant metastasis
had higher numbers of AgNORs, 4.0 (0.8), than tumours
without metastasis, 3.0 (0.9), (P = 0.078). Progressing tumours
(T-, N- and M-categories) had significantly more AgNORs
than non-progressing ones (Table III). Non-progressing (T)
WHO grade III tumours (n = 25) had lower numbers of
AgNORs, 3.9 (0.3) than progressing tumours (n = 21), 4.9
(0.4), (P = 0.0711) whereas grade I-II tumours could not be
Figure 1 Normal lymphocytes in a perivesical lymph node a,
having one to two AgNORs within each nucleus. In WHO grade
III bladder tumour b, numerous dispersed AgNORs and clusters
of AgNORs can be seen within each nucleus.
re-grouped. In a logistic multivariate regression analysis
AgNORs predicted progression independently (Table IV).
RR and RFP were related significantly to AgNOR count
(Table V). Diploid tumours with high numbers of AgNORs
had shorter RFPs than tumours with low numbers of
AgNORs (Table V) whereas aneuploid tumours could not be
regrouped. Tumours leading to cancer death had higher
numbers of AgNORs than non-fatal tumours (Table VI). In
survival analysis AgNORs predicted disease related survival
(Table VI, Figure 2) and diploid tumours could be sub-
divided according to AgNORs (Figure 3). In multivariate
survival analysis including clinical stage, WHO grade, papil-
larity and FCM variables AgNORs had no independent
predictive value.
Papillary tumours
AgNORs were related to clinical stage (P = 0.0021), WHO
grade (P<0.0001), DNA ploidy (P = 0.0140) and SPF (P =
0.0007) as seen in Table II. Progression in T-, N- and M-
categories was related to AgNORs (T; P = 0.0110, N; P =
0.0190, M; P = 0.0110). Non-progressing (T) tumours (n =
140) had a mean of 2.6 (0.9) AgNORs whereas 3.2 (0.2)
AgNORs was present in progressing tumours. AgNORs pre-
dicted independently progression in a multivariate analysisNUCLEOLAR ORGANISER REGIONS IN TRANSITIONAL CELL BLADDER CANCER 1141
Table II The mean (s.e.) values ofAgNORs subdivided according to
T-category, papillarity, WHO grade, DNA ploidy and SPF
Category Number AgNORs (s.e.) P-value
T-category
Ta 3 2.6 (0.3
TI 117 2.8 (0.1
T2 60 3.2 (0.1) 0.01la
T3 32 3.7 (0.3)
T4 17 3.5 (0.4)
Papillarity
Papillar 190 2.8 (0.1) <0.0001
Non-papillar 39 4.3 (0.3)
WHO grade
I 83 2.4 (0.1)
II 100 3.0 (0.1) <0.0001a
III 46 4.4 (0.3)
DNA ploidy
Diploid 129 2.8 (0.1)
Aneuploid 72 3.6 (0.2) 0.0010
SPF
< 10.0% 114 2.7 (0.1)
> 10.0% 61 3.7 (0.2) <0.0001
'Two-tailed analysis of variance; others Student's t-test.
Table Ill The mean (s.e.) numbers of AgNOR in progressing and
non-progressing bladder tumours
Progression Number AgNOR (s.e.) P-value"
T-category
No progression 163 2.8 (0.1)
Progression 66 3.6 (0.2) 0.0030
N-category
No progression 162 2.8 (0.1)
Progression 67 3.6 (0.2) 0.0010
M-category
No progression 159 2.8 (0.1)
Progression 70 3.6 (0.2) 0.0010
'Student's t-test.
Table IV The results oflogistic multiparameter regression analysis of
progression in T-category
Category s.e. Significance
All cases (n = 175)
AgNOR 0.3090 0.1222 0.0115
SPF 0.0422 0.0191 0.0273
Papillary tumours (n= 146)
SPF 0.0631 0.0219 0.0040
Ta-Ti tumours (n = 93)
AgNOR 0.3999 0.1667 0.0165
The analysis included T-category, WHO grade, papillarity, DNA
index (DI), SPF and the number of AgNORs. The independent
predictors at significance level of <0.055 are only shown. P = beta
coefficient of regression model; s.e. = standard error P.
Table V The recurrence-free period (RFP) (years) in all cases
(n = 229), in papillary tumours (n = 190), and in diploid tumours
(n = 129) subdivided according to number ofAgNORs
Category Number RFP (s.e.) P-value'
All cases
AgNOR 3.5 160 4.2(0.3)
AgNOR>3.5 69 2.5 (0.4) 0.0010
Papillary tumours
AgNOR 3.5 146 4.4 (0.4)
AgNOR>3.5 44 2.8 (0.5) 0.0125
Diploid tumours
AgNOR 3.5 103 4.4 (0.4)
AgNOR>3.5 26 2.3 (0.6) 0.0045
SPF
SPF 1I0.0% 127 4.1 (0.4)
SPF> 10.0% 66 2.3 (0.4) 0.0010
'Student's t-test. For comparison the RFP subdivided according to
SPF is shown.
Table VI The mean (s.e.) number ofAgNORs in tumours leading to
bladder cancer death, in patients dying ofintercurrent diseases and in
patients alive at the end of the follow-up
Subgroup Number AgNORs (s.e.) P-value"
All cases
Bladder cancer 73 3.7 (0.2)
Other diseases 72 2.9 (0.2) <0.0001
Alive 84 2.7 (0.1)
Papillary tumours
Bladder cancer 45 3.3 (0.2)
Other diseases 67 2.7 (0.1) 0.0038
Alive 78 2.6 (0.1)
Ta-TI tumours
Bladder cancer 14 3.4 (0.5)
Other diseases 47 2.9 (0.2) 0.0226
Alive 59 2.4 (0.1)
aTwo-tailed analysis of variance.
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Figure 2 Disease related survival of all patients subdivided ac-
cording to number of AgNORs. The difference in survival
between curves is significant (X2 = 12.1, P=0.0005). Curve A:
n = 160, AgNOR number K3.5; Curve B: n = 69, AgNOR number>3.5.
(Table IV). AgNORs were related to RFP (Table V) whereas
the RR could not be predicted by AgNORs. WHO grade
(P = 0.0582), DNA ploidy (P = 0.0261) and SPF (P =0.0747)
were related to RFP. AgNORs predicted disease related sur-
vival significantly (Table VI, Figure 4). In multivariate ana-
lysis AgNORs had no independent predictive value.
Ta-TI and T2-T3 tumours
A significant relationship between AgNOR count, papillarity
(P = 0.0060), WHO grading (P<0.0001), DNA ploidy (P =
0.0700) and SPF (P = 0.0028) was present. Progression in T-
(P=0.12), N (P=0.16) and M- categories (P=0.1l) was
related to AgNORs with a borderline significance. In a logis-
tic multiparameter analysis AgNORs had independent prog-
nostic values as predictors of progression (Table IV). the RR
(P = 0.12) and RFP (P = 0.18) were related to AgNORs with
a borderline significance. WHO grade (P = 0.118), DNA
ploidy (P = 0.069), SPF (P = 0.065) and papillarity (P =
0.098) predicted RFP. DNA ploidy (P = 0.0370) and SPF
(P = 0.0500) were significant predictors of RR. In diploid
tumours the RR was 2.5 (0.4) vs 5.1 (1.1) of aneuploidy
tumours (n = 26). Tumours with SPF < 15.0% had a mean
RR of 2.6 (0.4) in comparison to 10.4 (3.0) in tumours with
SPF> 15.0%. In diploid tumours AgNORs predicted RFP
to some degree (P = 0.20). In univariate survival analysis
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Figure 3 Disease related survival of patients with a diploid
bladder cancer subdivided according to number of AgNORs. The
difference in survival between the curves is significant (x2= 14.5,
P = 0.0001). Curve A: n = 103, AgNOR number <3.5; Curve B:
n = 26, AgNOR number>3.5.
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Figure 4 Disease related survival of patients with papillary blad-
der cancer subdivided according to number of AgNORs. The
difference in survival between the curves is significant (X2 = 8.4,
P = 0.0038). Curve A: n = 146, AgNOR number<3.5; Curve B:
n = 44, AgNOR number>3.5.
AgNORs predicted disease related survival (Figure 5) where-
as in multivariate analysis they had no independent predic-
tive value.
In- T2-T3 tumours AgNORs predicted progression in uni-
variate analysis (P = 0.0410) whereas they had no indepen-
dent predictive value in multivariate analysis. Non-progressing
tumours (T) (n = 49) had 3.0 (0.2) AgNORs whereas progres-
sing tumours (n = 43) had a mean of 3.7 (0.2) AgNORs.
AgNORs predicted bladder cancer related survival in uni-
variate analysis (X2
= 11.1, P = 0.004). In a multivariate ana-
lysis they had no independent predictive value.
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Figure 5 Disease related survival of patients with superficial
bladder cancer subdivided according to number ofAgNORs. The
difference in survival between the curves is almost significant
(X2 = 3.2, P = 0.0751). Curve A: n = 97, AgNOR number < 3.5;
Curve B: n = 23, AgNOR number>3.5.
Discussion
The present series has previously been analysed by morpho-
metry (Lipponen & Eskelinen, 1990a, 1990b; Lipponen et al.,
1990c) and DNA flow cytometry (Lipponen et al., 1991a).
The predictive value of clinical stage, papillarity and WHO
grade has been described in connection with these reports.
So, special emphasis is given to AgNORs which are subject
to controversies as prognostic variables or indicators of pro-
liferative activity in several malignancies (Giri et al., 1989;
Rushoff et al., 1990a; Sivridis & Sims, 1990; Delahut et al.,
1991; Eskelinen et al., 1991b) including transitional cell blad-
der cancer (Cairns et al., 1989; Ooms & Veldhuizen, 1989;
Mansour et al., 1990; Lipponen & Eskelinen, 1991a).
The AgNORs are located in acrocentric chromosomes,
each chromosome having two AgNORs. All AgNORs are
not visible in normal histological sections and usually one or
two may be present within the nucleus (Underwood & Giri,
1988). Accordingly 20 AgNORs may be visible in normal
nucleus before mitosis. Since in aneuploid cells the number of
chromosomes at any phase of cell cycle is higher than in
diploid cells higher AgNOR counts can be found in case
additional chromosomal material bears NOR sites. However,
AgNORs present active rRNA (Wachlter et al., 1986) and
the proliferative activity of a given cell determines the
number of AgNORs suggesting a relationship between the
number of AgNORs and SPF.
Aneuploid tumours as well as tumours with high SPF had
significantly higher numbers of AgNORs than diploid
tumours with low SPF. The results are in agreement with the
results in breast tumours (Giri et al., 1989; Eskelinen et al.,
1991b). Consequently, high grade tumours, non-papillary
tumours and muscle invasive tumours had higher AgNOR
counts since most of these tumours are aneuploid (Lipponen
et al., 1991b). The relationship between grade, papillarity and
AgNOR counts has been presented previously (Cairn et al.,
1989; Ooms & Veldhuizen, 1989; Lipponen & Eskelinen,
1991a) the present results supporting these findings. The
relationship between DNA flow cytometric data and AgNORs
has not been reported previously in transitional cell bladder
tumours.
The AgNORs were able to predict pelvic lymph node
involvement at the time at diagnosis as well as they predict
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axillary lymph node involvement in breast cancer (Sivridis &
Sims, 1990). The potential of AgNORs to predict pretreat-
ment lymph node metastasis is similar to that of DNA ploidy
and SPF in the same clinical material (Lipponen et al.,
1991b). Moreover, AgNORs were related significantly to pro-
gression postoperatively the results being in line with those
obtained by mitotic indexes (Lipponen & Eskelinen, 1990b,
Lipponen et al., 1990c) and DNA flow cytometry (Lipponen
et al., 1991b). The potential to predict progression in Ta-Ti
tumours may permit a more precise stratification of these
tumours like mitotic indexes (Lipponen et al., 1990c) or flow
cytometric data (Lipponen et al., 1991b). WHO grading
seems to be of rather limited value in predicting progression
in individual cases (Lipponen et al., 1990c). This is supported
by the ability of AgNORs to regroup WHO grade III
tumours in terms of progression. These latter results are
contradictory to observations presented previously (Mansour
et al., 1990), however, their series included 11 patients with a
short follow-up.
Aneuploid bladder tumours with high SPF reccur more
often having usually a shorter RFP than diploid ones (Blom-
jous et al., 1989) whereas WHO grade is a weak predictor of
RFP (Lipponen & Eskelinen, 1990a). In the present analysis
AgNORs predicted REF like SPF, DNA index or mitotic
activity (Lipponen et al., 1990c). It was unexpected that RFP
of diploid tumours could be further regrouped according to
their AgNOR number. This latter finding may be related to
intratumour heterogenity of DNA ploidy (Lipponen et al.,
1991b) or AgNORs are independent of DNA ploidy since the
proliferative status of a given cell determines the AgNOR
number (Wachtler et al., 1986). Aneuploid tumours could not
be regrouped, however. The relationship between AgNORs
and RFP in bladder cancer is consonant to results in breast
cancer in which AgNORs predict significantly RFP, too
(Eskelinen et al., 1991b). The differences in RR and RFP
could not be attributed to intravesical chemotherapy since it
had not significant predictive value in univariate analysis
(P = 0.213) or in multivariate analysis.
AgNORs were related to progression consequently predict-
ing disease related survival. In colon tumours (Rushoff et al.,
1990a; Ofner et al., 1990) and in renal cell tumours (Delahut
et al., 1991). AgNORs have been able to predict survival
significantly even within clinical stage categories (Delahut et
al., 1991). Accordingly, AgNORs predicted survival in papil-
lary bladder tumours, in superficial tumours and in muscle
invasive tumours. Surprisingly, diploid bladder cancers could
be stratified. As with recurrences, this latter result is with a
higher probability related to intratumour heterogenety of
DNA ploidy (Lipponen et al., 1991b). On the other hand,
SPF can regroup diploid tumours which suggest subgroups
of diploid bladder tumours with different proliferative poten-
tials. Patients dying of their bladder cancer had higher
AgNOR counts than patients dying of intercurrent diseases
or being alive after follow-up. However, in a multivariate
analysis of survival including clinical, histological, flow cyto-
metric variables and AgNORs, the AgNORs had no indepen-
dent prognostic value.
The methodology in the present analysis differs from that
of many other analyses presented until now (Cairns et al.,
1989; Mansour et al., 1990; Lipponen & Eskelinen, 1991a).
Firstly, the areas of analysis were selected aiming at finding
the most atypical fields for measurement whereas previous
studies have used random sampling. We feel that selective
sampling led us to improved predictive results. The impor-
tance of selection of fields for analysis cannot be over-
emphasised since bladder tumours often show intratumour
heterogenity of malignancy (Lipponen et al., 1991b). In
accordance with the above selective morphometry (Lipponen
& Eskelinen, 1990a, Lipponen & Eskelinen, 1990b) has given
good prognostic results in bladder cancer. Secondly, 5Jm
thick sections were used in contrast to 3l.m thick sections
were used in contrast to 3 lm sections used in most studies.
In 3 jim sections dispersed AgNORs free within the nucleus
may be lost and the data are 'compressed' between high- and
low-count specimens (Crocker et al., 1989). In the present
analysis the microscope was focused to find the maximum
number of AgNORs visible at the same time. The number of
nuclei counted was limited to 70 since the counting of
AgNORs is time consuming and moreover the methodo-
logical studies have shown that the standard error of the
mean does not vary significantly after 50-60 nuclei has been
counted (Rushoff et al., 1990b). In the present analysis the
intraobserver variation of the mean was 5 x % which is
comparable to results observed by other researchers (Man-
sour et al., 1990; Rushoff et al., 1990b; Sivridis & Sims,
1990).
From the results we can conclude that AgNORs are relat-
ed to proliferative activity and malignancy in bladder cancer.
AgNORs have independent prognostic value in superficial
bladder tumours as predictors of progression. In muscle
invasive tumours classic prognostic factors and flow cytome-
tric variables are more important predictors. The results
suggest that AgNORs can be used as an adjunct to histo-
logical grading, flow cytometry and mitotic indexes in pre-
dicting clinical behaviour in superficial bladder tumours. It is
hard to imagine the use of AgNORs alone in predicting
individual cases of bladder cancer due to considerable over-
lap in AgNOR counts between malignant and more benign
bladder tumours. The results encourage for further studies
giving special emphasis to standardisation of measurement
process and this refers to morphometric methods, in partic-
ular (Rushoff et al., 1990a; Rushoff et al., 1990b).
The study was supported by a research grant from Savon Sy6para-
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